Diabetic Foot Ulcers
Conditions
Keywords
diabetic foot ulcers, chitosan, isosorbide dinitrate spray
Brief summary
The prevalence of diabetic foot ulceration in the diabetic population is 4-10%; the condition is more frequent in elder patients. It is estimated that about 5% of all patients with diabetes present a history of foot ulceration, while the lifetime risk of diabetic patients developing this complication is 15%. The majority (60-80%) of foot ulcers will heal, while 10-15% of them will remain active, and 5-24% of them will finally lead to limb amputation within a period of 6-18 months after the first evaluation , 2 out of 3 patients with a limb amputation could also be involved in a new amputation in the next year; higher or in the other leg , Eighty-five percent of lower-limb amputations in patients with diabetes are preceded by foot ulceration. The management of chronic diabetic foot ulcers (DFU) suggests multi-disciplinary approaches including control of diabetes, orthotic shoe wear, off-loading device, wound care and surgery in selected cases. However, treatment of DFU remains challenging because of unsatisfactory results from surgical and non-surgical treatments. Many adjunctive therapies are designed to improve the care of DFU including negative pressure wound therapy , ultrasound, recombinant human platelet-derived growth factor-BB (rPDGF-BB) Hyperbaric oxygen and acellular matrix product among others.
Detailed description
A randomized, placebo controlled, double-blind Clinical trial was designed. 60 Patients with diabetic foot ulcers in grade I and II of the classification of Wagner, with leg arm index\> 0.8 and without specific treatment for foot ulcers referred to the experimental and clinical Therapeutic Institute will be included. All patients give written informed consent; previously the protocol was approved for the bioethics committee of the CUCS, of the Guadalajara University, registration number 030-2010. Patients with another type of topical medication will be excluded. Isosorbide dinitrate spray (2.5 mg). Preparation of chitosan Hydrogels: The composition of gel formulation will be given prior training. ISDN and chitosan gel will be applied handled under aseptic conditions to the wound, and covered with sterile bandages. The patients will be evaluated every 2 weeks (macroscopic study and measurement of the ulcerated area) until 6 views. A second biopsy will be done one week before the finalization of the treatment of 15 weeks. The biopsies will be embedded on paraformaldehyde (4%) and paraffin. Sections of 5 µm were analyzed by a pathologist to determine hypertrophic and hyperplasic capillaries, inflammation and cellular matrix using Hematoxylin & eosin and Masson's trichrome stains. An immunohistochemical stain was also realized to evaluate several molecular markers such as α-SMA (abcam, Cambridge, MA), Desmin (abcam, Cambridge, MA), VEGF (abcam, Cambridge, MA) and Von Willebrand Factor (Chemicon, CA). (figure 1) Statistical analysis: It will be done using SPSS program for Windows Version 10.0, the results of quantitative variables were expressed in average and standard deviation. The differences between baseline and subsequent pharmacologic intervention measurements will be investigated with the Wilcoxon test. The Mann Whitney U test will be used to compare groups. Frequencies by categories as well as percentages will be quantified for qualitative variables. Comparisons between groups were performed with Chi2. For all comparisons p \< 0.05 will be considered as significant.
Interventions
Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
placebo
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with diabetic foot ulcers in grade I and II of the classification of Wagner * with leg arm index\> 0.8 and * without specific treatment for foot ulcers referred to the experimental and clinical
Exclusion criteria
* Patients with another type of topical medication * patients with diabetic foot ulcers in grade III and * with leg arm index \<0.8
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biopsies | 75 days | Histological changes in ulcers |
Participant flow
Pre-assignment details
ADDITIONAL PARTICIPANTS WERE INCLUDED ANTICIPATING PARTICIPANTS WHO DO NOT COMPLETE THE CLINICAL TRIAL
Participants by arm
| Arm | Count |
|---|---|
| Active Comparator: Chitosan Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
And
Placebo in the same pharmacological presentation that Isosorbide dinitrate spray | 17 |
| Active Comparator: Isosorbide Dinitrate Spray Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
And
Placebo in the same pharmacological presentation that Chitosan | 17 |
| Combination: IDS and Chitosan Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
And
Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine | 17 |
| Placebo Comparator: Placebo Placebo in the same pharmacological presentation that both, IDS and Chitosan. | 17 |
| Total | 68 |
Baseline characteristics
| Characteristic | Active Comparator: Chitosan | Active Comparator: Isosorbide Dinitrate Spray | Combination: IDS and Chitosan | Placebo Comparator: Placebo | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 17 Participants | 17 Participants | 17 Participants | 17 Participants | 68 Participants |
| Diameter of the ulcer | 10.5 centimeters STANDARD_DEVIATION 5.8 | 12.1 centimeters STANDARD_DEVIATION 7 | 11.4 centimeters STANDARD_DEVIATION 8.2 | 15.8 centimeters STANDARD_DEVIATION 9.3 | 12.3 centimeters STANDARD_DEVIATION 7.5 |
| Sex: Female, Male Female | 8 Participants | 8 Participants | 8 Participants | 8 Participants | 32 Participants |
| Sex: Female, Male Male | 9 Participants | 9 Participants | 9 Participants | 9 Participants | 36 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 17 | 0 / 17 | 0 / 17 | 0 / 17 |
| other Total, other adverse events | 0 / 17 | 0 / 17 | 0 / 17 | 0 / 17 |
| serious Total, serious adverse events | 0 / 17 | 0 / 17 | 0 / 17 | 0 / 17 |
Outcome results
Biopsies
Histological changes in ulcers
Time frame: 75 days
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Comparator: Chitosan | Biopsies | α-smooth muscle actin | 2.46 UI/dL | Standard Deviation 0.6 |
| Active Comparator: Chitosan | Biopsies | Von Willebrand Factor | 2.38 UI/dL | Standard Deviation 0.65 |
| Active Comparator: Chitosan | Biopsies | vascular endothelial growth factor-A | 2.23 UI/dL | Standard Deviation 0.8 |
| Active Comparator: Chitosan | Biopsies | desmin | 2.3 UI/dL | Standard Deviation 0.8 |
| Active Comparator: Isosorbide Dinitrate Spray | Biopsies | desmin | 2.5 UI/dL | Standard Deviation 0.6 |
| Active Comparator: Isosorbide Dinitrate Spray | Biopsies | vascular endothelial growth factor-A | 2.6 UI/dL | Standard Deviation 0.6 |
| Active Comparator: Isosorbide Dinitrate Spray | Biopsies | Von Willebrand Factor | 2.28 UI/dL | Standard Deviation 0.82 |
| Active Comparator: Isosorbide Dinitrate Spray | Biopsies | α-smooth muscle actin | 2.64 UI/dL | Standard Deviation 0.6 |
| Combination: IDS and Chitosan | Biopsies | vascular endothelial growth factor-A | 2.43 UI/dL | Standard Deviation 0.6 |
| Combination: IDS and Chitosan | Biopsies | desmin | 2.6 UI/dL | Standard Deviation 0.6 |
| Combination: IDS and Chitosan | Biopsies | Von Willebrand Factor | 2.31 UI/dL | Standard Deviation 0.8 |
| Combination: IDS and Chitosan | Biopsies | α-smooth muscle actin | 2.56 UI/dL | Standard Deviation 0.6 |
| Placebo Comparator: Placebo | Biopsies | Von Willebrand Factor | 2.15 UI/dL | Standard Deviation 0.5 |
| Placebo Comparator: Placebo | Biopsies | α-smooth muscle actin | 2.07 UI/dL | Standard Deviation 0.6 |
| Placebo Comparator: Placebo | Biopsies | desmin | 2.3 UI/dL | Standard Deviation 0.6 |
| Placebo Comparator: Placebo | Biopsies | vascular endothelial growth factor-A | 2.07 UI/dL | Standard Deviation 0.7 |